Imatinib Activates Pathological Hypertrophy by Altering Myocyte Calcium Regulation

BACKGROUND: Imatinib mesylate is a selective tyrosine‐kinase inhibitor used in the treatment of multiple cancers, most notably chronic myelogenous leukemia. There is evidence that imatinib can induce cardiotoxicity in cancer patients. Our hypothesis is that imatinib alters calcium regulatory mechani...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Barr, Larry A., Makarewich, Catherine A., Berretta, Remus M., Gao, Hui, Troupes, Constantine D., Woitek, Felix, Recchia, Fabio, Kubo, Hajime, Force, Thomas, Houser, Steven R.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2014
Materias:
Original Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4213285/
https://ncbi.nlm.nih.gov/pubmed/24931551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12173
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares